Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer...
Month: September 2020
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups Vaccitech Ltd, a clinical-stage...